| Victoza (liraglutide) / Novo Nordisk |
2012-001208-39: A new therapeutic approach to prevent acute complications in type 2 diabetes: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® against the cOnventional insulin therapy: GALILEO Neuer Therapieansatz zur Verhinderung akuter Komplikationen bei Typ 2 Diabetes: Der Effekt einer Kombination des GLP-1 Analogons Liraglutide mit Insulin LEvemir im Vergleich zur kOnventionellen Insulintherapie: GALILEO |
|
|
| Ongoing | 2 | 32 | Europe | Insulin Levemir, Victoza, insulin aspart, EMEA/H/C/000528, EMEA/H/C/001026, EMEA/H/C/000308, Injection | Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel, Medizinische Universität Wien | diabetes mellitus type 2, inadequate metabolic control, indication for insulin therapymyocardial lipid accumulation and left-ventricular function, retinal changes, microabluminuria, beta-cell-function, endothelial dysfunction Diabetes mellitus Typ 2,unzureichende Stoffwechselkontrolle, Indikation für InsulintherapieMyokardiale Lipidakkumualtion und Herzfunktion, retinale Veränderungen, Mikroalbuminurie, Beta-Zell-Funktion, Ednotheliale Dysfunktion, Typ 2 Diabetes, bad metabolic control, need for insulin therapyacute secondary diabetes-related complications Typ 2 Diabetes, schlechte Stoffwechseleinstellung, insulinpflichtigakute Folgeerkrankungen, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2011-003335-63: Effects of liraglutide on pancreatic function in type 2 diabetic patients with secondary failure to oral hypoglycemic agents. Effetti di liraglutide sulla funzione pancreatica nei pazienti con diabete tipo 2 in fallimento secondario agli ipoglicemizzanti orali. |
|
|
| Ongoing | 2 | 80 | Europe | Solution for injection, Tablet, Coated tablet, VICTOZA*SC 2PEN 3ML 6MG/ML, GLIMEPIRIDE TEVA*20CPR 4MG, LEVEMIR*FLEX 5PEN 3ML 100UI/ML, METFORMINA TEVA IT*60CPR RIV1G | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, UNIVERSITA' DI PISA, NOVO NORDISK | Type 2 Diabetes mellitus Diabete mellito tipo 2, Type 2 Diabetes Diabete tipo 2, Diseases [C] - Hormonal diseases [C19] | | | | |
2015-000825-35: Liraglutide to Short Bowel Syndrome, a cross-over study Liraglutide til jejunostomipatienter, et overkrydsningsstudie |
|
|
| Ongoing | 2 | 16 | Europe | Solution for injection in pre-filled pen, Victoza | Rigshospitalet Blegdamsvej, Rigshospitalet Blegdamsvej | Short bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytes; restricted oral/enteral nutrition to reduce intestinal losses; disease-related hypophagia; lack of adaptive hyperphagia; accelerated gastrointestinal transit time, Patients with a jejunostomy and a short bowel syndrome, Diseases [C] - Digestive System Diseases [C06] | | | | |
2011-003572-36: The role of gut hormones replacement in improving blood flow to the brain after stroke that affects swallowing. |
|
|
| Ongoing | 2 | 40 | Europe | Liraglutide, Liraglutide, Liraglutide | Royal Devon & Exeter NHS Foundation Trust, University of Exeter, , University of Exeter | We plan to give a synthetic form of GLP-1 (Liraglutide) that is already available and licensed for use in patients with diabetes in the UK, to patients who have had an acute stroke, in order to determine whether increased levels protect the brain during its recovery, resulting in better recovery. | | | | |
2012-002073-60: Liraglutide in the treatment of polycystic ovary syndrome (LIPOS study) |
|
|
| Ongoing | 2 | 106 | Europe | Liraglutide (Victoza), Victoza, Victoza | University of Warwick, Novo Nordisk Ltd | Polycystic ovary syndrome (PCOS). | | | | |
2014-001381-96: A trial investigating liraglutide on the liver glucose production during induced hypoglycaemic in type 1 diabetes mellitussubjects |
|
|
| Ongoing | 2 | 15 | Europe | Victoza, Victoza | Medizinische Universität Graz / Endokrinologie und Stoffwechsel, Medizinische Universität Graz / Endokrinologie und Stoffwechsel | Diabetes Mellitus Type 1 | | | | |
2016-002045-36: Lifestyle induced weight loss and Liraglutide in the treatment of NASH |
|
|
| Ongoing | 2 | 50 | Europe | Victoza, Suspension for injection, Victoza | University of Oxford, Clinical Trials and Research Governance, University of Oxford | Non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease - fat and inflammation in the liver, Diseases [C] - Digestive System Diseases [C06] | | | | |
2016-004797-18: A pilot study in the use of the GLP-1 agonist liraglutide in the treatment of short bowel |
|
|
| Ongoing | 2 | 5 | Europe | Victoza, EU/1/09/529/001-005, Solution for injection in pre-filled pen, Victoza | Imperial College London, St Mark's Foundation | Intestinal failure with an underlying aetiology of short bowel, Intestinal failure due to short bowel is defined as a condition whereby a patient has insufficient intestinal length to absorb enough fuilds and/or nutrients to sustain life without IV supplementation, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-000043-31: Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients Efficacité et tolérance du Liraglutide sur la perte de poids chez les patients hémodialysés diabétiques de type 2 obèses |
|
|
| Not yet recruiting | 2 | 30 | Europe | Liraglutide, Injection, Liraglutide | Groupe Hospitalier Paris Saint-Joseph, Groupe Hospitalier Paris Saint-Joseph | obese type 2 diabetic hemodialysis patients, obese type 2 diabetic hemodialysis patients, Body processes [G] - Metabolic Phenomena [G03] | | | | |
2020-005098-29: OPTI-STEMI is a randomized, non-profit, open label, multicentre phase II trial for the evaluation of new therapeutic strategies to reduce microvascular obstruction and to optimize revascularization in non-culprit stenosis in STEMI myocardial infarction. OPTI-STEMI è uno studio randomizzato, no-profit, open label, multicentrico di fase II per la valutazione di nuove strategie terapeutiche per ridurre l’ostruzione microvascolare e per ottimizzare la rivascolarizzazione in stenosi non-culprit nell’infarto miocardico STEMI. |
|
|
| Ongoing | 2 | 520 | Europe | Metoprololo, Atorvastatina, Eparina sodica, Adenosina, Colchicina, Clopidogrel, Ticagrelor, Liraglutide, Prasugrel, Ramipril, Acido acetilsalicilico, Abciximab, [NA], Infusion, Tablet, Solution for injection | DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II, Ministero dell’Istruzione, dell’Università e della Ricerca Progetto MIUR codice 2017PZY5K7 | Patients with acute ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) defined by at least one non-culprit stenosis (NCS) with angiographic severity between 30 and 90% Pazienti infarto miocardico acuto con sopraslivellamento del tratto ST (STEMI) e con malattia coronarica multivasale (MVD) definita da almeno una stenosi non culprit (NCS) con severità angiografica tra il 30 ed il 90%, Patients with microvascular obstruction with non-culprit stenosis, i.e. with partial stenosis, between 30% and 90%, of coronary vessels. Pazienti con ostruzione microvascolare con stenosi non-culprit, ossia con stenosi parziale, tra il 30% e il 90%, dei vasi coronarici., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
LIRADIAL, NCT04529278: Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients |
|
|
| Active, not recruiting | 2 | 18 | Europe | Liraglutide | Groupe Hospitalier Paris Saint Joseph | Diabetes Mellitus, Type 2, Hemodialysis, Obese | 01/23 | 12/23 | | |
NATRIURETIC, NCT04535960: Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "" Trial |
|
|
| Recruiting | 2 | 36 | Canada | Empagliflozin 25 MG + Liraglutide 1.8 MG, Generic names are above, listed, Liraglutide 1.8 MG + Empagliflozin 25 MG | University Health Network, Toronto | Type 2 Diabetes Mellitus | 10/23 | 10/23 | | |
NCT04763564: Efficacy of Liraglutide Therapy in Patients With IPAA |
|
|
| Terminated | 2 | 8 | US | Liraglutide Pen Injector, Victoza, Placebo Pen Injector, Saline | University of North Carolina, Chapel Hill, Novo Nordisk A/S | Pouchitis, Irritable Pouch Syndrome | 10/23 | 10/23 | | |
| Recruiting | 2 | 40 | US | AD109 | Apnimed | OSA | 09/24 | 12/24 | | |
| Enrolling by invitation | 2 | 42 | Europe | Victoza®, Placebo | University of Oulu, Oulu University Hospital, Tampere University Hospital, Turku University Hospital | Health behaviour change, Physical inactivity, Quality of life | 06/24 | 06/24 | | |
NCT02960659: Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes |
|
|
| Completed | 1/2 | 24 | US | Liraglutide, Metformin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Children's National Research Institute | Type 2 Diabetes | 05/22 | 05/22 | | |
NCT05268237: Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 1/2 | 15 | RoW | Liraglutide, Placebo | Biolingus, Chinese University of Hong Kong | Diabete Type 2 | 05/24 | 07/24 | | |
NCT03182426: Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) |
|
|
| Completed | 1/2 | 22 | Canada | Plerixafor, Mozobil, Alemtuzumab, Lemtrada, Anakinra, Kineret, Etanercept, Enbrel, Liraglutide, Victoza | University of Alberta, Alberta Innovates Health Solutions | Diabetes Mellitus, Type 1 | 07/24 | 07/24 | | |
NCT03011021: Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes |
|
|
| Recruiting | 1/2 | 40 | RoW | Liraglutide, UCB-Treg, Insulin | Second Xiangya Hospital of Central South University | Type1 Diabetes Mellitus, Autoimmune Diabetes | 06/25 | 06/25 | | |
